Creo Medical Group PLC (AIM:CREO)
London · Delayed Price · Currency is GBP · Price in GBX 10.25
-0.13 (-1.25%)
Oct 16, 2026, 3:37 PM GMT
Creo Medical Group Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 7 | 6 | 4 | 4 | 27.2 | 25.16 |
| 7 | 6 | 4 | 4 | 27.2 | 25.16 | |
Revenue Growth | 52.17% | 50.00% | 0% | -85.29% | 8.10% | 166.85% |
Cost of Revenue | 4.1 | 3.6 | 2.1 | 1.7 | 14 | 13.58 |
Gross Profit | 2.9 | 2.4 | 1.9 | 2.3 | 13.2 | 11.59 |
Selling, General & Admin | 21.5 | 22.9 | 29.2 | 29.1 | 44 | 41.54 |
Other Operating Expenses | -1.1 | -1.2 | 0.4 | -0.4 | -0.1 | -0.05 |
Operating Expenses | 20.4 | 21.7 | 29.6 | 28.7 | 43.9 | 41.49 |
Operating Income | -17.5 | -19.3 | -27.7 | -26.4 | -30.7 | -29.91 |
Interest Expense | -0.4 | -0.3 | -0.4 | -0.2 | -0.2 | -0.21 |
Interest & Investment Income | 0.3 | 0.6 | 0.2 | 0.7 | 0.1 | 0.03 |
Earnings From Equity Investments | 1.5 | 1.7 | - | - | - | - |
Other Non Operating Income (Expenses) | - | - | - | - | -0.1 | -0.25 |
EBT Excluding Unusual Items | -15.8 | -17.3 | -27.9 | -25.9 | -30.9 | -30.34 |
Merger & Restructuring Charges | -0.1 | -0.2 | -1.1 | - | - | - |
Other Unusual Items | - | - | - | -0.5 | - | - |
Pretax Income | -15.9 | -17.5 | -29 | -26.4 | -30.9 | -30.34 |
Income Tax Expense | - | - | -1.2 | -2.7 | -4 | -5.74 |
Earnings From Continuing Operations | -15.9 | -17.5 | -27.8 | -23.7 | -26.9 | -24.6 |
Earnings From Discontinued Operations | -4.2 | 22.8 | -0.9 | 2 | - | - |
Net Income | -20.1 | 5.3 | -28.7 | -21.7 | -26.9 | -24.6 |
Net Income to Common | -20.1 | 5.3 | -28.7 | -21.7 | -26.9 | -24.6 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 416 | 412 | 370 | 313 | 181 | 164 |
Shares Outstanding (Diluted) | 416 | 412 | 370 | 313 | 181 | 164 |
Shares Change | 4.68% | 11.48% | 18.20% | 72.61% | 10.28% | 5.54% |
EPS (Basic) | -0.05 | 0.01 | -0.08 | -0.07 | -0.15 | -0.15 |
EPS (Diluted) | -0.05 | 0.01 | -0.08 | -0.07 | -0.15 | -0.15 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -21.8 | -19.1 | -22.5 | -22.8 | -28.1 | -31.99 |
Free Cash Flow Per Share | -0.05 | -0.05 | -0.06 | -0.07 | -0.15 | -0.20 |
Gross Margin | 41.43% | 40.00% | 47.50% | 57.50% | 48.53% | 46.04% |
Operating Margin | -250.00% | -321.67% | -692.50% | -660.00% | -112.87% | -118.86% |
Profit Margin | -287.14% | 88.33% | -717.50% | -542.50% | -98.90% | -97.75% |
Free Cash Flow Margin | -311.43% | -318.33% | -562.50% | -570.00% | -103.31% | -127.13% |
EBITDA | -16.9 | -18.6 | -26.7 | -24.7 | -28.5 | -28.15 |
EBITDA Margin | -241.43% | - | - | - | -104.78% | -111.88% |
D&A For EBITDA | 0.6 | 0.7 | 1 | 1.7 | 2.2 | 1.76 |
EBIT | -17.5 | -19.3 | -27.7 | -26.4 | -30.7 | -29.91 |
EBIT Margin | -250.00% | - | - | - | -112.87% | -118.86% |